Crescent Biopharma (CBIO) Interest & Investment Income (2013 - 2026)
Crescent Biopharma (CBIO) reported Interest & Investment Income of $1.4 million for Q1 2026, up 669.15% year-over-year from $188000.0 in Q1 2025, and up 32.05% quarter-over-quarter from $1.1 million in Q4 2025.
Crescent Biopharma (CBIO) Interest & Investment Income (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 11 years of Interest & Investment Income data on file, last reported at $1.4 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $1.4 million, up 669.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (up 559.76% YoY), and the FY2025 annual result was $2.9 million, up 207.4% from the prior year.
- Interest & Investment Income climbed to $1.4 million in Q1 2026 per CBIO's latest filing, from $1.1 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.4 million in Q1 2026 and troughed at $7069.0 in Q1 2022.
- A 5-year average of $514190.0 and a median of $378312.5 in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income soared 9180.3% in 2022, then slumped 65.64% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at $378265.0 in 2022, then surged by 35.41% to $512194.0 in 2023, then tumbled by 65.64% to $176000.0 in 2024, then surged by 522.16% to $1.1 million in 2025, then soared by 32.05% to $1.4 million in 2026.
- Business Quant data shows CBIO's Interest & Investment Income at $1.4 million in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 313,000.00 |
| Mar 31, 2025 | 188,000.00 |
| Dec 31, 2024 | 176,000.00 |
| Jun 30, 2024 | 262,288.00 |
| Mar 31, 2024 | 378,360.00 |
| Dec 31, 2023 | 512,194.00 |
| Sep 30, 2023 | 610,978.00 |
| Jun 30, 2023 | 671,033.00 |
| Mar 31, 2023 | 581,668.00 |
| Dec 31, 2022 | 378,265.00 |
| Sep 30, 2022 | 243,597.00 |
| Jun 30, 2022 | 85,588.00 |
| Mar 31, 2022 | 7,069.00 |
| Dec 31, 2021 | 4,076.00 |
| Sep 30, 2021 | 4,625.00 |
| Jun 30, 2021 | 5,221.00 |
| Mar 31, 2021 | 5,846.00 |